Moreover, amplifications or mutations in Set2 homologs in human cancers has been linked to chemotherapy resistance [68–70], including to chemotherapeutics that cause DNA lesions repaired by NER (e.g., cisplatin and melphalan). The gene discussed is SETD2; the disease is cancer.